GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting at 55 trial locations

Overseen By GEMINI NSCLC

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Tempus AI

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

1200 Participants Needed

Trial Summary

What is the purpose of this trial?

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.

Research Team

Virginia Rhodes, MD

Principal Investigator

Tempus AI, Inc.

Eligibility Criteria

Inclusion Criteria

I might have lung cancer that can be surgically removed and I agree to a diagnostic procedure.

My cancer treatment follows standard guidelines, regardless of genetic changes.

I am 18 years old or older.

Treatment Details

Interventions

• Observation

Participant Groups

Group I: Cohort 2 Experimental Treatment 1 Intervention

Cohort 2 will include patients with stage IV disease receiving first line immunotherapy (as monotherapy or in combination with chemotherapy).

Group II: Cohort 1 Experimental Treatment 1 Intervention

Cohort 1 will include patients with early-stage (Stages I-IIIB) who are candidates for treatment with curative intent, surgery with or without perioperative (neoadjuvant or adjuvant) therapy.

Who Is Running the Clinical Trial?

Tempus AI

Lead Sponsor

Trials

18

Recruited

20,700+

Tempus Labs

Lead Sponsor

Trials

17

Recruited

20,200+

AstraZeneca

Industry Sponsor

Trials

4,491

Recruited

290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology